Bifogade filer
PDF
Kurs
0,00%
Likviditet
7,84 MSEK
Kalender
| Est. tid* | ||
| 2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-17 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2025-05-27 | - | Årsstämma |
| 2025-05-15 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-16 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-18 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-11 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2023-05-10 | - | Årsstämma |
| 2023-05-10 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-14 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-13 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2022-05-12 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-08 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2020-05-07 | - | Årsstämma |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-12 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2019-05-09 | - | Årsstämma |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-06 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-17 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2018-05-03 | - | Årsstämma |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-13 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2017-05-03 | - | Årsstämma |
| 2017-05-03 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-14 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-17 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
| 2016-05-03 | - | Årsstämma |
| 2016-03-30 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Lund, Sweden - 13 October 2021 - Camurus (NASDAQ STO: CAMX) today announces the appointment of Jon U. Garay Alonso as the new Chief Financial Officer (CFO), and a member of Camurus' Management Team, effective from 1 February 2022.
Jon brings more than 20 years of experience from various finance positions within leading international pharmaceutical and MedTech companies, such as Baxter, Gambro, Convatec and Bristol Myers Squibb. He is currently Finance Director, Europe at Baxter International, where he is heading the finance department supporting the Medication Delivery & Pharmaceutical Business.
"We are delighted to welcome Jon to Camurus as our new CFO. With his extensive experience in corporate and operational finance and strong track-record of driving business growth, Jon will be an excellent addition to our management team and an important contributor to the company's continued development and international expansion." says Fredrik Tiberg, Camurus' President and CEO.
"I very much look forward to joining Camurus, to become part of a great team, and contributing to a strong company development and giving patients access to innovative treatments", says Jon.
Eva Pinotti-Lindqvist, Camurus' current CFO, will maintain her position until Jon's employment begins, and thereafter be available to ensure a smooth transition.
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
This information was submitted for publication at 5:00 pm CET on 13 October 2021.